When Antibiotics Fail: Investigating Superbugs and Drug Resistance | FRONTLINE

Added:

Addie's Infection
Resistant Bacteria
India's Superbug
New Threat Arrives
Hospital Outbreak
New Resistance
Why Resistance Grows
Facing the Crisis
Lasting Impact

Addie's Infection

2:00
Playing Section
  • 1

    A healthy 11-year-old girl develops a severe staph infection and septic shock.

  • 2

    Her condition worsens in the hospital despite antibiotics, leading to organ failure.

Fundamental differences between bacterial and viral pathogens, specifically why antibiotics are ineffective against viral infections.
The principles of natural selection and evolution, particularly how genetic mutations and environmental pressures drive rapid adaptation in microbial populations.
The mechanisms of horizontal gene transfer (conjugation, transformation, and transduction) by which bacteria share resistance genes.
Basic mechanisms of antibiotic action, such as the inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid replication.
Alternative antimicrobial therapies currently under research, such as bacteriophage (phage) therapy, CRISPR-based antimicrobials, and monoclonal antibodies.
The principles of clinical 'antibiotic stewardship' and public health policy interventions aimed at regulating antibiotic use in both healthcare and agriculture.
The economic and regulatory challenges in the pharmaceutical industry that disincentivize the research and development of new classes of antibiotics.
Global epidemiological surveillance strategies and hospital-acquired infection (HAI) prevention protocols designed to contain multidrug-resistant organisms (MDROs).
3.6M views40.9Klikes53:16@frontlineOriginal Release: 2021-12-22

The emergence of antibiotic-resistant superbugs, driven by overuse of antibiotics and economic disincentives in pharmaceutical research, poses an existential threat to modern medicine, as evidenced by cases like Addie Rasecich (who required a lung transplant after her infection became untreatable) and David REI (who contracted NDM-1 during his travels), highlighting how the post-antibiotic era is arriving faster than new treatments can be developed.